Akebia Therapeutics $AKBA: Vafseo, VOICE and the Kidney Disease Business

01 Three scenarios for the renal franchise

A constructive scenario begins with durable Vafseo adoption. The product would continue to gain appropriate patients, treatment persistence would support repeat demand, and net sales would advance sufficiently to absorb the decline in Auryxia. Commercial spending would become more productive as the prescriber base expands, rather than rising indefinitely with each incremental patient. The company would then have more freedom to fund clinical work without placing the same burden on outside capital.

The VOICE presentation could support that scenario if the detailed result is clinically meaningful and relevant to the populations making up the commercial opportunity. Clinicians may respond differently to a result that is statistically strong but difficult to apply in practice and one that addresses an important treatment decision in an understandable way. The quality of evidence, the approved label and the treatment workflow remain essential parts of the commercial discussion.

In a middle scenario, Vafseo grows but the transition takes longer. Existing prescribers may continue using it while broader adoption moves more gradually. Auryxia’s erosion could offset part of the growth, and the commercial organization could require continued investment. The company would remain operationally active and clinically relevant, but a clear improvement in consolidated profitability would take more time to emerge.

That middle scenario is especially useful because it does not require a dramatic clinical disappointment. A rollout can be slower because of contracting, reimbursement, treatment protocols, inventory timing or conservative clinical behavior. Such factors can delay financial improvement even when the product remains attractive to some users. The relevant question becomes how expensive the delay is and how well the company preserves its options during it.

A contrary scenario combines commercial underperformance with rising development or financing pressure. Vafseo adoption could fall short of the level needed to compensate for Auryxia, or product economics could be less favorable as the cost base normalizes. A clinical result might have less influence on prescribing than expected. Pipeline spending could then compete more directly with the cash required to sustain the commercial business.

Debt refinancing is another variable in that contrary scenario. A refinance can improve timing and flexibility, but it can also introduce costs, covenants or other obligations. If financing and commercial progress are both difficult, management has fewer choices. A company with valuable products can still face a difficult equity outcome when its claims on future cash flow expand faster than the cash-generating business.

These scenarios describe combinations of operating outcomes. They do not require a numerical probability or a share-price target to be useful. Their value is in identifying what observable evidence would move the business from one path toward another: persistent patient use, product revenue, spending discipline, stronger cash generation, useful clinical results and clearly disclosed financing terms.

02 A kidney disease company with two economic clocks

Akebia’s commercial business and its development pipeline operate on different clocks. Product sales can be measured each quarter. Clinical development is organized around enrollment, follow-up, analysis and regulatory milestones. The shareholder is exposed to both, and a useful company analysis keeps those clocks connected without pretending that they move at the same speed.

The commercial clock matters because it generates immediate evidence about adoption and economics. A product can have an attractive clinical rationale and still require time to become established in a treatment pathway. Quarterly revenue shows one part of that process, but it needs context from prescribing, persistence, net pricing and the costs associated with selling and supporting the product.

The development clock creates a longer-horizon opportunity. Clinical programs may address substantial unmet needs, but their progress is not a smooth extension of current product revenue. A trial may produce a result that supports the next stage, a result that changes the development plan or a result that ends a program. The associated spending is real in every case.

A focused renal franchise can provide advantages across those clocks. Commercial relationships, disease knowledge, medical expertise and operational infrastructure may help the company recognize useful development opportunities. Nevertheless, the existence of a shared disease area does not automatically make every program equally valuable. Each asset still needs its own evidence, economics and development plan.

The practical benefit of examining Akebia as a franchise is that it prevents either product sales or pipeline enthusiasm from dominating the entire analysis. Vafseo is a commercial execution question. Auryxia is a cash contribution and erosion question. Praliciguat and ebribafusp are clinical development questions. Their combined result determines the company’s ability to fund and build a durable business.

03 Vafseo: the approved product and the clinical boundaries

Vafseo contains vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Its U.S. indication covers anemia due to chronic kidney disease in adults who have received dialysis for at least three months. The prescribing information also carries serious cardiovascular and thrombotic risk warnings. Those boundaries are central to understanding the product rather than a detail appended to a growth story. Current prescribing information

An oral treatment changes one feature of therapy delivery, but the commercial meaning of that feature depends on the patient’s circumstances and the treatment setting. Dialysis patients already interact frequently with healthcare providers. A different route of administration therefore needs to fit the clinical and operational workflow, rather than relying on the assumption that oral treatment is always more convenient or preferred.

The safety discussion also has an economic dimension. A medicine’s commercial opportunity depends partly on how prescribers balance its benefits, risks, monitoring requirements and alternatives. A company’s marketing objective can be broader than the uses supported by its current label. The approved indication is the relevant starting point for present commercial activity.

Product growth can be assessed through several layers. The first is initial prescribing. The second is persistence among appropriate patients. The third is repeat demand across an expanding prescriber base. The fourth is the resulting net revenue after reimbursement and commercial adjustments. A strong result at one layer is useful, but the full business needs the layers to work together.

Clinical evidence can influence that process. A dataset may help clinicians understand which patients are likely to benefit, how treatment compares with existing approaches and what practical issues require attention. The evidence has to be considered alongside the existing safety information. A favorable study does not erase the importance of a product’s warnings or replace the obligations attached to approved use.

For shareholders, Vafseo’s importance is therefore greater than a single growth rate. It is the asset around which the company is attempting to strengthen its commercial identity and financial trajectory. The most persuasive long-term evidence would be a combination of sustained demand, appropriate use, improving economics and a cost base that supports rather than consumes the product’s growth.

04 VOICE: the questions behind the late-breaking presentation

The August 5 results release already disclosed a planned interim analysis involving 2,116 participants. The hierarchical composite of all-cause mortality and hospitalizations produced win odds of 1.16, with a 95% confidence interval of 1.06–1.28 and p=0.0016. The result was driven by fewer hospitalizations and met the prespecified stopping criteria. The composite result does not isolate a mortality benefit. October’s presentation can add clinical detail to this existing result, while the approved U.S. dosing instructions remain separate. Interim result

The June 30, 2026 Form 8-K gives the components behind that headline. The interim analysis used a June 1, 2026 data cutoff, and the primary investigator stopped the trial after a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee. VOICE was designed as a randomized, open-label, active-controlled, non-inferiority trial sponsored by U.S. Renal Care, and the filing states that the interim result established both non-inferiority and superiority on the primary composite. Hospitalizations were 1.11 versus 1.23 per patient-year with Vafseo versus ESA, an incidence rate ratio of 0.90 (95% CI 0.824–0.988). Mortality showed no statistically significant difference: 8.77% versus 8.78% per 100 patient-years, an incidence rate ratio of 1.00 (95% CI 0.718–1.391). The win odds of 1.16 therefore describe a composite advantage carried by hospitalizations; they are not a 16% reduction in deaths. June 30 Form 8-K

The announced VOICE presentation evaluates three-times-weekly vadadustat against an ESA in patients receiving in-center hemodialysis. Its October conference slot follows the company’s earlier communication of a favorable interim safety result. A full presentation gives the clinical audience an opportunity to examine the study’s structure and the result in more detail. Conference announcement

The first question is the population. A result in one dialysis population may not apply identically to every patient or setting. Baseline risk, previous treatment, comorbidities, exposure and follow-up can affect interpretation. A clinically useful result needs a sufficiently clear description of the people studied for clinicians to judge its relevance.

The second question is the endpoint. Composite outcomes can capture important burdens of disease, but their interpretation depends on the components. A result driven mainly by one event type may have a different practical meaning from a consistent improvement across several important outcomes. Event counts and the relative contribution of each component help place the headline in context.

The third question is the size and durability of the effect. Statistical significance is one property of a result. Clinical significance depends on the magnitude of the difference, its uncertainty and the seriousness of the outcomes involved. A treatment decision is informed by all of these elements, rather than the strength of a probability value alone.

The fourth question is consistency. Results across subgroups can be informative, but smaller groups also introduce uncertainty. Apparent differences between groups may reflect chance, baseline differences or genuine treatment heterogeneity. The main result and the study’s design deserve priority over an isolated attractive subgroup.

The fifth question is implementation. If a treatment approach appears useful, clinics still need to consider dosing, monitoring, patient selection and approved use. The commercial implications of a study emerge through that implementation process. The path from a conference presentation to wider adoption is neither automatic nor necessarily immediate.

The sixth question is the relationship to the existing label. The study schedule and the approved dosing instructions are separate pieces of information. A presentation can motivate scientific discussion or further regulatory work, but current use remains governed by the relevant prescribing information. That distinction protects the analysis from turning a research schedule into a claim of a new approved regimen.

A robust reading of VOICE can support a stronger assessment of the franchise while retaining these distinctions. It can identify what the result adds, what remains uncertain and what practical decisions it may inform. That is more useful than treating the late-breaking designation itself as proof of clinical superiority or commercial success.

05 Commercial adoption: moving from a launch to a durable business

The Q2 release reported growth in Vafseo revenue, patients and prescribers. Those observations support the existence of commercial progress. Their economic significance depends on what happens after the first prescription and how efficiently the organization converts clinical interest into repeat demand. Commercial update

The release quantified that progress. Vafseo net product revenue of $21.3 million represented a 34% increase over the first quarter. More than 10,500 patients were active on Vafseo in Q2, a 41% increase from the end of Q1 2026, and the total number of prescribers increased to approximately 1,200, an increase of approximately 17% versus Q1. Active patients, new starts and prescribers are different measures, so each should be compared with its own prior value rather than combined into a single adoption rate. Q2 2026 release

The first-quarter release added two details about the shape of that base. First refill adherence through the end of March was approximately 86% for patients treated under an observed dosing protocol for which the company has historically received patient-level data, and approximately two thirds of all Q1 patients were treated under such a protocol. Approximately 20% of patients and 30% of prescribers in Q1 were from dialysis organizations other than U.S. Renal Care. A first-refill rate in one protocol subgroup is an early persistence signal; it is not a measure of long-term retention across all patients. Q1 2026 release

A launch can benefit from concentrated attention, initial stocking and the activity of early adopters. A durable business needs continued use beyond those initial effects. Patient persistence and repeat prescribing are therefore important complements to the size of the current patient base. A growing base with weak persistence can have different economics from a similarly sized base with stable use.

Prescriber breadth is another factor. Demand concentrated among a small group can be commercially useful, but it may be vulnerable to changes in local protocols or individual preferences. Broader adoption can improve resilience, provided that the company can support it without an unsustainable increase in commercial spending.

Commercial efficiency requires attention to the relationship between incremental revenue and incremental expense. A sales organization can create value while expanding, but a mature business needs evidence that additional scale improves its economics. The question is whether the organization becomes more productive as adoption grows, rather than requiring a nearly proportional increase in costs.

The treatment setting can make adoption more complex. Dialysis organizations must consider medical protocols, operational routines, payer requirements and patient care. A new treatment has to fit within those systems. Commercial enthusiasm alone cannot resolve all of the practical details involved in that transition.

The most useful operating evidence would therefore connect several observations: consistent patient growth, repeat use, broader prescribing, acceptable reimbursement and a stabilizing commercial cost base. No single indicator substitutes for that combination. Together, they can show whether Vafseo is becoming an established franchise asset.

06 Auryxia: erosion changes the meaning of growth

Auryxia remains an important part of Akebia’s current revenue, but the Q2 release described lower sales and continued pressure from generics and pricing. That changes how Vafseo’s progress should be evaluated. The company is managing growth in one product while the contribution from another contracts. Q2 franchise results

The August Form 10-Q identifies the specific pressures. Auryxia lost exclusivity in March 2025, after which Akebia’s authorized generic distributor began selling an authorized generic version in the U.S. On March 11, 2026, Teva received approval of its abbreviated new drug application for a generic version of Auryxia, which subsequently entered the market. The company states that it has experienced, and expects to continue to experience, a significant reduction in Auryxia sales volume as a result, and that the extent of the future impact depends on factors including its dialysis contracts and the timing and number of additional generics. Q2 2026 Form 10-Q

The relevant arithmetic is at the company level. Revenue growth from a newer product may first compensate for the decline of an older one. Only after that offset does it translate into consolidated growth. A product can therefore perform well while the total business remains under pressure.

The margin implications can also differ from the revenue implications. Products may have different cost structures, commercial requirements and lifecycle economics. Replacing one dollar of revenue with another does not guarantee the same profit contribution. Product mix matters, particularly during a period of transition.

A declining product can still contribute useful cash. The issue is how much contribution remains after costs and how long it can support the broader organization. Management needs to balance maintaining an economically useful franchise with avoiding spending that is no longer justified by its future contribution.

This makes Auryxia a central part of the financing discussion. If its contribution erodes faster than Vafseo’s grows, the commercial transition uses more resources. If the company manages the decline efficiently while Vafseo becomes more productive, the same transition can be more manageable. The pace and cost of the change deserve attention together.

07 Financial performance: consolidated results tell a different story

The Q2 financial picture contains a useful tension: progress in the growth product and pressure in the consolidated business. That tension is common during a product transition, but it should be visible in the analysis. A product headline can be accurate while giving an incomplete view of the company’s economic position.

Revenue needs to be considered with operating expenses and the cost of goods sold. Growth has more financial value when it produces additional gross profit that can absorb the commercial and development cost base. A business that grows revenue while costs rise as quickly may have less operating leverage than the headline suggests.

Akebia’s Q2 release highlighted another accounting consideration: Vafseo cost of goods sold included pre-launch inventory for which some manufacturing-related expenses had previously been recognized in research and development. This means reported early product economics can differ from the economics of replenishing inventory under a normalized cost structure. Cost disclosure

The 10-Q puts numbers on that difference. Cost of product and other revenue for Vafseo was $1.0 million in the second quarter; had the Vafseo inventory sold in the quarter been valued at cost, it would have been $3.5 million. For the first six months the corresponding figures were $2.4 million and $9.7 million. At June 30, 2026, Akebia held $18.2 million of reduced-cost Vafseo inventory, and the company expects Vafseo cost of product to increase, reflecting the full cost of manufacturing, once that inventory has been used. Current Vafseo gross margin is therefore flattered by a finite inventory position. Q2 2026 Form 10-Q

That accounting treatment is important because gross margin is often used to project future profitability. A projection should consider the cost of supplying future demand, not simply assume that an early inventory position will persist. The product’s long-term margin depends on manufacturing, supply arrangements, net pricing and the mix of business.

Net loss and cash use also need separate treatment. Net income includes accounting items that may not correspond to current cash movements. Cash flow reflects working capital, payment timing and other uses of resources. A quarter’s loss cannot be converted mechanically into a precise monthly cash requirement.

The stronger financial trajectory would be one in which Vafseo’s gross profit grows, the decline in Auryxia becomes more manageable, commercialization spending becomes more productive and pipeline investment remains within a credible funding plan. Those developments would reinforce one another. A single improved quarterly metric would be a useful signal, but the broader pattern would carry more weight.

08 Cash, runway and the refinancing condition

The August 5 Form 10-Q makes the financing condition precise. Principal repayments were scheduled to begin January 1, 2027. Management’s two-year funding expectation assumed a refinancing that would defer those payments; without it, management estimated funding for at least twelve months from the filing date, including anticipated revenue. At June 30, principal was $52.439 million, compared with a $49.563 million carrying value. Scheduled 2027 principal payments were $50.558 million, maturity was January 29, 2028, and the interest rate at quarter-end was 11.00%. These are the obligations disclosed for that reporting period. Debt and liquidity disclosures

The same filing sets out the terms of the BlackRock facility that any refinancing would replace or amend. The term loan accrues interest at one-month term SOFR, subject to a 4.25% floor, plus a 6.75% margin, with an overall cap of 15.00% on the all-in rate. It is secured by substantially all of the company’s existing and after-acquired assets, including intellectual property. The credit agreement requires Akebia either to maintain at least $15.0 million of cash in one or more controlled accounts or to report trailing twelve-month revenue of $150.0 million, both measured monthly, and prepaying the loan before maturity carries a fee of 1.0% to 4.0% of the amount prepaid. Because either test satisfies the requirement, the cash condition remains the relevant backstop if trailing revenue declines. Akebia’s SEC filings through October 13, 2026 did not include a report of a completed refinancing, so the January 2027 amortization schedule above remains the disclosed obligation. Q2 2026 Form 10-Q

Existing cash provides flexibility, but the significance of that flexibility depends on the operating plan and obligations. Akebia’s stated funding expectation includes commercial and other revenue as well as refinancing. It is therefore a plan involving several sources and uses of capital, rather than an unconditional cash reserve covering a fixed period.

Refinancing can improve an operating company’s position by extending maturities or changing repayment timing. It can also affect interest expense, security, covenants and strategic flexibility. The economic result depends on the terms. Completion, proceeds, costs and the resulting obligations are more informative than the existence of a refinancing objective.

Commercial revenue is another variable in the funding plan. If the product transition proceeds well, the business can support more of its spending internally. If revenue or margins are weaker, the same plan may require adjustments. A funding horizon based partly on expected revenue naturally changes with the commercial result.

Pipeline spending introduces additional flexibility and tradeoffs. A company can modify the pace of development, but doing so may change the timing of evidence and the value of an opportunity. Reducing spending can preserve cash while delaying a milestone. Increasing spending can accelerate development while bringing financing requirements forward.

A simple historical cash-to-loss ratio can be a useful scale comparison, but it is not a complete runway forecast. Debt payments, working capital, clinical activity, product mix and noncash accounting items can all change the result. The responsible interpretation is to connect the cash balance with the specific assumptions of the operating plan.

The quality of the funding discussion improves when management discloses what the capital is intended to achieve. A reserve has more strategic meaning when it funds a clearly defined commercial and clinical sequence. Resources, milestones and the ability to respond to setbacks belong in the same analysis.

09 Pipeline architecture: optionality with real development costs

Akebia’s rare kidney programs can broaden the franchise beyond anemia and its current products. The attraction is a focused clinical area with significant unmet needs. The financial reality is that additional programs also require funding, operational attention and evidence appropriate to their intended indications.

Portfolio breadth can be valuable when it creates several independent routes to clinical success. It can be less valuable when programs compete for limited resources or share unresolved risks. The number of assets is therefore less informative than their scientific rationale, development stage, differentiation and funded path to useful data.

The clinical stage matters. Phase 2 generally asks questions about activity, dose, safety and the design of later development. An encouraging result can strengthen the case for a program, but the size and nature of the evidence needed for approval may be much greater. Development value changes as uncertainty is reduced, not simply as time passes.

Rare kidney diseases also have distinct biology and treatment needs. A shared renal label does not make the patient populations interchangeable. A program may address one mechanism or subgroup particularly well while having a different role elsewhere. Indication-specific evidence is essential.

For the company, the pipeline’s value is linked to capital allocation. Development spending should advance the most important unresolved questions while preserving the ability to support the commercial franchise. A portfolio that produces useful evidence within a sustainable plan is more persuasive than a broad list of programs without a clear funding sequence.

10 Praliciguat and the FSGS development question

Akebia identifies praliciguat as a Phase 2 program in focal segmental glomerulosclerosis, or FSGS. The October conference announcement includes both preclinical research and a poster describing the Phase 2 trial. Those are separate categories of evidence: a laboratory or model-based rationale and a clinical study intended to evaluate patients. Kidney Week program

The trial design is now public. Praliciguat is an oral, once-daily soluble guanylate cyclase (sGC) stimulator that Akebia licensed from Cyclerion Therapeutics in June 2021, and the 10-Q states that the first patient in the Phase 2 FSGS trial was dosed in December 2025. The ClinicalTrials.gov record (NCT07268638) describes a randomized, double-blind, placebo-controlled study in adults with biopsy-confirmed FSGS, with an estimated enrollment of 60. Participants are randomized 1:1 to praliciguat or placebo for an initial 24 weeks, after which all receive praliciguat open-label for an additional 24 weeks. The primary outcomes are the change from baseline in urine protein-to-creatinine ratio (UPCR) up to week 24 and safety up to week 52; partial remission at week 24, defined as a 40% UPCR reduction and UPCR below 1.5 g/g, is a secondary outcome. The registry lists an estimated primary completion of June 2027, an estimate rather than a committed data date. UPCR measures proteinuria; a reduction would be a meaningful Phase 2 signal, not on its own proof that the drug preserves kidney function over the long term. NCT07268638 · Q2 2026 Form 10-Q

The value of a clinical program depends partly on how clearly it defines the disease population. FSGS is a disease pattern with heterogeneous causes and clinical circumstances. A treatment study needs to establish the patients for whom its hypothesis is relevant. That definition affects enrollment, interpretation and the potential future role of the medicine.

An early clinical signal can be useful, but its significance depends on the endpoint, duration and the context of other treatments. Short-term changes may or may not translate into the outcomes that matter over a longer period. A development plan needs to connect its early measurements with a clinically meaningful next stage.

The competitive question is equally important. A new treatment must have a role within an evolving disease landscape. Potential differentiation can involve effectiveness, tolerability, convenience or the population addressed. Each possible advantage requires evidence rather than an assumed premium attached to being a new program.

A successful Phase 2 result would therefore have several properties: a coherent signal, acceptable safety, an interpretable population and a plausible next development step. A weak or ambiguous result could require a revised design, additional work or a narrower indication. Those possible paths have different costs and timelines.

Praliciguat should be viewed as a development opportunity with the capacity to add to the franchise. Its value is not equivalent to an approved-product revenue forecast. The transition between those categories depends on clinical evidence, regulatory progress and the capital required to advance the program.

11 Ebribafusp: a basket study across complement-mediated disease

Akebia announced first dosing in the ebribafusp Phase 2 basket study on September 14. The program addresses rare complement-mediated kidney diseases, including IgA nephropathy, lupus nephritis and C3 glomerulopathy. The Q2 update described initial data expected in 2027. This timing is management guidance and remains subject to trial progress. First patient announcement

Ebribafusp, previously known as AKB-097 and ADX-097, is a tissue-targeted C3d-Factor H fusion protein complement inhibitor. Akebia acquired the program from Q32 Bio under an asset purchase agreement dated November 28, 2025, paying $7.0 million upfront and a further $3.0 million at the six-month anniversary, with development and regulatory milestones of up to $94.5 million. Before the acquisition, ebribafusp had been evaluated in a Phase 1 trial in healthy volunteers, which is not evidence of efficacy in kidney disease. Q2 2026 Form 10-Q

According to the Q2 release, the open-label basket trial is expected to enroll up to 30 patients in total across the three diseases, dosed subcutaneously once weekly. It will measure UPCR, eGFR and pharmacokinetics, together with blood and urine complement biomarkers intended to show whether ebribafusp reduces complement activity in the kidney while avoiding complement inhibition in the blood. The ClinicalTrials.gov record (NCT06419205) lists a single-group, unmasked design with an estimated 30 participants, treatment-emergent adverse events up to 30 weeks as the primary outcome, UPCR and eGFR changes up to 26 weeks as secondary outcomes, and an estimated primary completion of February 2028. With roughly 30 patients spread over three diagnoses, initial data will be best read cohort by cohort and as a test of mechanism; reduced systemic inhibition is the design hypothesis, not a demonstrated clinical advantage. Q2 2026 release · NCT06419205

A basket design can create an efficient way to investigate a mechanism in several related diseases. Its interpretation still needs to respect the differences between the populations. A promising result in one cohort may justify further work there without proving an equivalent opportunity in every other cohort.

The program’s first dosing milestone is concrete because it marks the start of patient treatment. Its economic significance is the opportunity to begin generating clinical evidence. Enrollment, treatment duration and follow-up then determine when and how informative that evidence becomes.

Complement-mediated disease has attracted substantial development activity. That increases the importance of understanding a program’s intended role. A useful candidate needs more than a biologically relevant target; it needs a benefit-risk profile and practical application that can compete within the particular disease.

Study size and design affect the strength of conclusions. An open-label early study can help identify activity and safety patterns, but later development may require a different level of comparative evidence. Early enthusiasm should therefore be connected to the questions the study can actually answer.

For Akebia, ebribafusp creates a potential route to a broader rare-disease franchise. That route has value only to the extent that evidence supports continued development and the company can fund the next stages on sensible terms. The first patient milestone advances the program; the clinical results will determine how much uncertainty it removes.

12 Competition: treatment pathways are the relevant market

Akebia competes within treatment decisions rather than within a ticker category. In anemia, the relevant alternatives are the therapies and protocols used by clinicians and dialysis organizations. In rare kidney disease, each program faces a disease-specific clinical and commercial landscape.

Competition can operate through effectiveness, safety, administration, monitoring, reimbursement and familiarity. A product may be attractive on one dimension while requiring more work on another. The commercial result depends on how the full package fits the decisions of patients, clinicians, providers and payers.

Established treatments also benefit from existing routines. A newer medicine must often overcome the practical cost of changing those routines. A compelling clinical result can help, but adoption may still require education, contracting and operational adjustments. This is one reason clinical progress and commercial progress can occur at different speeds.

Competition in development can change before a new asset reaches commercialization. Other programs may produce results, enter a market or alter the expected standard of care. A company’s development strategy needs enough flexibility to respond while preserving the scientific purpose of its studies.

The strongest position would be evidence-based differentiation in populations where the treatment provides a useful advantage. A broad market estimate alone gives little guidance about that position. The quality of the product’s role, supported by data and acceptable economics, is the more durable basis for analysis.

13 Product economics and the difference between demand and value

Growing demand is useful, but shareholder value depends on the economics of serving it. Net pricing, gross margin, commercial expense, supply costs and the capital needed to sustain the business all influence how product growth translates into cash generation.

The most important pricing disclosure concerns 2027. In its August 10-Q, Akebia explains that reimbursement to dialysis facilities for Vafseo changes when the product moves from the Transitional Drug Add-on Payment Adjustment, or TDAPA, period to the post-TDAPA period beginning in 2027. The company expects to price Vafseo within the range of the price for ESAs, which are currently priced significantly lower than Vafseo’s current price. As a result, while it expects to sell a higher unit volume of Vafseo in 2027 than in 2026, it expects Vafseo revenues to decrease significantly in 2027 compared with 2026. The company has not disclosed a specific 2027 price. In analytical terms, the 2026 revenue run-rate is not a base that can simply be extrapolated: unit growth, net price per unit and the move to full-cost inventory will all change together, while BlackRock principal payments are scheduled to begin in the same year. Q2 2026 Form 10-Q

Patient counts and revenue can move differently. Changes in treatment persistence, reimbursement, discounts, timing and mix may affect net sales per patient. A stable relationship can improve the visibility of the business, while an unstable one makes forecasting more difficult.

Commercial spending has a similar relationship with growth. A successful launch can require upfront investment. The value of that investment becomes clearer as the business scales. The organization needs to demonstrate that incremental activity creates enough gross profit to support its operating structure.

Inventory accounting adds another layer. A current gross margin may reflect a specific inventory history or cost treatment. The economics of future production can differ. That is why a sustainable margin assessment needs to consider replenishment and the longer-term supply structure.

The company also has to allocate resources between its current commercial products and future opportunities. Pipeline investment can create substantial value, but it is a use of current resources before it generates revenue. Product economics and development strategy need to be evaluated together.

A durable financial improvement would therefore involve more than a larger sales number. It would involve a product mix and cost structure that support stronger operating cash generation, together with a development plan that remains financeable. That combination is what turns commercial progress into a more resilient franchise.

14 Intellectual property: protection supports a business, not a forecast

The Q2 release described an expanded Vafseo patent portfolio, including Orange Book-listed patents and potential term extension for a composition-of-matter patent. Intellectual property can support the commercial opportunity by protecting particular inventions and aspects of the product. The scope, validity and duration of that protection determine its practical significance. Patent update in Q2 results

The details matter for the duration question. The Q2 release reported a new Orange Book-listed patent, U.S. Patent No. 12,569,474, expiring in June 2034, and eligibility for a five-year patent term extension on a composition-of-matter patent, which would extend that patent’s term to mid-2032. The Vafseo portfolio now includes 14 Orange Book-listed patents, with expiration dates out to 2036. Eligibility for an extension is not the same as a granted extension, and listed expiry dates describe the patents, not the outcome of any future challenge. Q2 2026 release

The existence of patents does not determine demand. It can provide a framework within which a company develops a product’s commercial value, but clinicians still need evidence and the business still needs favorable economics. Protection and execution are complementary.

Patent portfolios also contain different types of claims. Their economic value depends on what competitors would need to do to enter or compete and on the legal position of the claims. A count of patents is therefore a limited measure of a product’s competitive protection.

Potential extensions deserve the same care as other future milestones. Eligibility, applications and actual granted terms are distinct events. A forecast should reflect the status that has been disclosed rather than assuming the most favorable possible outcome.

For shareholders, intellectual property is best considered alongside the product’s clinical role, commercial adoption and expected economic contribution. Strong protection can support a useful franchise. It cannot by itself turn an uncertain rollout into guaranteed cash flow.

15 Leadership and the operating choices that matter

John P. Butler is identified as Akebia’s chief executive in the Q2 announcement. The most useful assessment of management is the quality of decisions and execution, rather than a narrative about personal confidence. The company’s current position requires coordination across commercialization, finance and clinical development. Management commentary

Recent governance and insider filings are routine rather than directional. In April, Akebia appointed Philip J. Vickers, Ph.D., President and Chief Executive Officer of Solu Therapeutics, to its Board of Directors. A Form 4 filed August 10 reports that Mr. Butler exercised 350,000 stock options on August 6, 2026, an option exercise rather than an open-market purchase; the filing notes that his holdings include 1,500 shares bought on June 30 under the employee stock purchase plan. A Form 4 filed July 1 reports that Erik Ostrowski, Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer, sold 56,019 shares on June 29 in an automatic sell-to-cover transaction to meet tax withholding on vesting restricted stock units, under instructions adopted on September 8, 2025. Neither transaction, on its own, says much about management’s view of the business. Q2 2026 release · Butler Form 4 · Ostrowski Form 4

Commercial leadership can be assessed through the productivity of the rollout. Useful signs include appropriate growth, coherent explanations of product mix and a clear connection between spending and results. The analysis should consider how management responds when adoption is slower or more expensive than expected.

Financial leadership is visible in capital planning. A credible plan identifies resources, obligations, milestones and the choices available if assumptions change. Refinancing is part of that discussion. So are spending discipline and the cost of preserving the pipeline.

Clinical leadership is visible in study design and the interpretation of results. The company needs to invest in work that answers meaningful questions and communicate findings with sufficient detail. A measured explanation of limitations can be more informative than a broad claim of potential.

The key management challenge is to preserve strategic options while moving the franchise forward. That may require prioritizing some opportunities over others. A successful business is not one that pursues every possible program; it is one that converts selected opportunities into useful clinical and financial outcomes.

16 Capital structure and the per-share result

Akebia disclosed a $75 million Jefferies at-the-market equity program, with $28.6 million of capacity remaining at June 30, 2026, and a $250 million S-3 shelf registration. The August 5 filing reported sales of 3,138,107 common shares for approximately $3.4 million gross and $3.2 million net proceeds during the first six months. Program capacity is permission to issue securities under specified terms; the net proceeds are the cash actually raised in that period. Neither the shelf ceiling nor unused ATM capacity is cash on the balance sheet. ATM and shelf disclosures

A growing business and a favorable per-share outcome are related, but they are not the same measure. Debt, equity issuance, employee compensation and other claims on the business can influence how its value is distributed. The financing discussion belongs alongside the operating story.

Equity financing may provide resources for a useful clinical or commercial milestone. Its economic significance depends on the capital raised, the ownership issued and the value created by the funded work. Dilution should therefore be analyzed in relation to what the financing enables, while remaining visible as a cost to existing holders.

Debt can preserve equity ownership at issuance but creates its own obligations. Interest, repayment schedules, collateral and covenants can affect the company’s future choices. A refinance may change these features, making the completed terms important to the analysis.

Employee equity also affects the future share count. Compensation can help a company retain important personnel, but the resulting ownership claims are part of the economic structure. A per-share assessment needs a consistent definition of the denominator.

The strongest operating improvement would be one that reduces dependence on external financing while retaining enough flexibility to fund attractive development. Until that point, capital structure remains a significant variable in the shareholder outcome.

17 A valuation framework without a mechanical price target

A valuation framework for Akebia needs to separate the current franchise from development opportunities. Commercial products can be assessed through sales, margins, expenses, lifecycle and cash generation. Pipeline assets require assumptions about clinical outcomes, development costs, timing and eventual commercialization.

Using one revenue multiple for the whole company can conceal important differences. A growing product and a product facing generic erosion have different trajectories. A pipeline asset has a different risk profile again. A useful framework recognizes these distinctions before combining them.

A commercial scenario should consider the pace of Vafseo adoption, the remaining contribution of Auryxia, normalized cost of goods and the productivity of the commercial organization. Changes in those assumptions can substantially alter the expected cash-generating capacity of the franchise.

A pipeline scenario needs an explicit development path. The stage of evidence, the next study, the required financing and the competitive landscape all affect its economic value. A large disease opportunity is only one input. It does not substitute for a credible path to a product.

Cash and debt then connect enterprise economics with equity value. The relevant cash balance is dated, and future financing assumptions need to be visible. The share count must be consistent with the claims being valued. Mixing historical financial data with an unspecified current denominator can create a misleadingly precise result.

The practical purpose of this framework is to identify the operating assumptions that matter most. It can show why two observers reach different conclusions without requiring a single price target. The business will provide evidence through adoption, margins, clinical results and financing; those are the inputs that should change the assessment.

18 Milestones and the evidence needed at each stage

The near-term conference event is confirmed, but its significance depends on the information presented. The date creates a known opportunity for clinical communication. The result’s completeness and relevance determine what the event adds to the franchise assessment.

The commercial milestones are continuous. Quarterly product revenue, patient use, prescriber breadth and spending provide recurring evidence about the rollout. Their value increases when the trends reinforce one another. A growing product with improving economics carries a different implication from a growing product supported by rapidly rising costs.

Pipeline milestones have a longer cadence. Enrollment, treatment and follow-up create the basis for results. A first patient milestone demonstrates that a study has begun treating participants. Later data determine whether the scientific and clinical hypothesis has been strengthened.

Financing milestones are discrete. A completed refinance or equity transaction has defined terms, proceeds and obligations. These need to be evaluated as actual changes in the company’s financial position, rather than an extension of management’s earlier objectives.

The operating sequence matters. A strong clinical communication can support the commercial discussion, commercial progress can support funding, and funding can sustain the pipeline. The company benefits when that sequence is coherent. Delays or setbacks in one part can change the demands placed on the others.

19 Risks, falsifiers and the central business test

The principal commercial risk is that Vafseo grows too slowly, or with insufficient economic contribution, to support the franchise transition. Evidence against a strong commercial thesis would include persistent weakness in demand, poor retention, unfavorable reimbursement or a cost base that fails to become more productive.

The principal financial risk is that assumptions supporting the operating plan prove too optimistic. Revenue, margins, refinancing and development spending all affect the funding horizon. Several unfavorable changes together would be more consequential than an isolated quarterly fluctuation.

The principal clinical risk is that future evidence provides less support than expected for the product or pipeline. A conference presentation may be informative without changing practice materially. A Phase 2 result may require additional work or a different program design. The appropriate response is to reassess the specific development path.

The principal capital-allocation risk is an imbalance between commercial needs and pipeline ambitions. A focused franchise still needs priorities. Funding every possible program at the same pace could reduce flexibility, while underinvesting in a valuable opportunity could delay future growth.

Safety and regulatory requirements remain fundamental. Product warnings and approved use shape current commercial activity. Development programs have their own standards for evidence and regulatory progression. A favorable business narrative cannot replace those requirements.

The central test is whether Akebia can turn Vafseo’s progress into a stronger consolidated business while generating useful rare-disease evidence within a sustainable financial plan. That test is observable over time. Product revenue, cost structure, cash generation, completed financing and clinical results will show whether the franchise is becoming more resilient.

20 The quarterly revenue bridge in plain numbers

The transition can be understood by comparing the two products with the consolidated result. In the Q2 release, Vafseo revenue increased from $13.3 million in the prior-year quarter to $21.3 million. Auryxia moved from $47.2 million to $25.5 million. The increase in the newer product was therefore smaller, in dollars, than the decline in the older one. Total reported revenue moved from $62.5 million to $49.1 million. These comparisons refer to Q2 2026 against Q2 2025, rather than sequential quarters.

The bridge explains why a favorable Vafseo growth headline can coexist with a weaker consolidated result. It also identifies the business challenge more precisely: the newer franchise needs sufficient additional economic contribution to support both the decline in the established product and the costs of growth. Product revenue is one part of that contribution; sustainable gross profit and spending efficiency complete the picture.

A useful next-quarter assessment would compare those movements again using the same definitions. It would examine the pace of the revenue transition, the commercial cost base and the costs attached to future supply. A single period need not settle the long-term question, but a sequence of periods can show whether the transition is becoming more manageable. That comparison is a framework for interpreting operating evidence, not a projection of future sales or share-price performance.

Reported quarterly comparison

Primary sources

• Q2 2026 results and business highlights, August 5
• VOICE and Kidney Week presentation schedule, October 6
• Ebribafusp first patient announcement, September 14
• Vafseo prescribing information, DailyMed
• FDA initial approved label
• Akebia investor relations

Frequently asked questions

What is the main commercial asset? Vafseo is Akebia’s central growth product. Auryxia remains part of the revenue base but faces generic and pricing pressure.

What is the next confirmed event? The announced VOICE late-breaking presentation is October 23, 2026, from noon to 12:15 p.m. Mountain Time at ASN Kidney Week in Denver.

Does the conference presentation change approved use? A scientific presentation and an approved-label change are distinct. Current use remains governed by the relevant prescribing information.

Why can Vafseo grow while company revenue declines? Growth in one product can be offset by a larger decline in another. The consolidated result captures the combined franchise.

Is the stated funding horizon based only on cash? Management’s Q2 statement included expected commercial and other revenue and a plan to refinance the senior secured term loan, alongside existing cash.

What does first dosing in the ebribafusp trial mean? Patient treatment has begun in the study. Subsequent clinical data will determine the program’s development implications.

Is the Health Score a recommendation? No. It is an editorial assessment of resources, catalysts, capital needs and execution. It does not predict returns.

What would strengthen the business assessment? Sustained appropriate adoption, improving product economics, controlled spending, useful clinical evidence and financing that preserves flexibility would reinforce the franchise.

This company analysis is educational and informational. It is not investment advice, a recommendation to buy or sell securities, or guidance on treatment. Readers should conduct their own research and consult qualified professionals where appropriate.